- The magazine
- Cancer Biology
- Chromatography & Mass Spectrometry
- Contract Research
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & Rapid Micro Methods (RMMs)
- Process Analytical Technology (PAT) & Quality by Design (QbD)
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- About us
- Contact us
Stem Cells - Articles and news items
Novartis announces global research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need…
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory…
The promise held by induced pluripotent stem cells for research and regenerative medicine.
Workshop preview – Cell based assays for screening.
Cardiac stem cells.
Stem Cells Roundtable.
Stem cell therapies: Assuring safety.
Role of pluripotent stem cells in neurotoxicology testing: Impacts and applied innovations.
The Canadian physician William Osler said: “The person who takes medicine must recover twice, once from the disease and once from the medicine.” Indeed, all medicines have side effects – some of which may complicate a patient’s treatment, or in extreme cases may even be fatal. Of concern is the fact that side effects of drugs are often difficult or impossible to predict from preclinical studies, and infamous cases of drugs causing permanent injury or even death of patients in clinical trials illustrate the severity of this problem.
Late stage attrition of drugs is costly for pharmaceutical companies, contributing to the rise of drug prices and delays of drug delivery to market. Better prediction of compound efficacy and safety at early stages of drug development relies on improvement of the models used for pre-clinical testing. The availability of human embryonic stem (hES) cells and, more recently, induced pluripotent stem (iPS) cells may transform the landscape of drug discovery. Here we provide an overview of human pluripotent stem cell features that make them amenable to predictive toxicology and discuss how chemical screens that aim to find drugs that modulate stem cell fates may provide a paradigm for using stem cells in drug discovery.
Genomics, Issue 2 2011 / 19 April 2011 / Janet L. Paluh, Associate Professor Nanobioscience, College of Nanoscale Science and Engineering, University at Albany SUNY and Guohao Dai and Douglas B. Chrisey, Biomedical Engineering, Rensselaer Polytechnic Institute
There is no other biomedical frontier that offers the stunning potential of human pluripotent stem cells and their progenitors in therapeutic applications to ease human suffering or in their ability to provide insights into development and diseases. Cell plasticity for reprogramming has revealed new opportunities in cell-based therapies and informed on lineage specification. What precisely defines each stem cell type or its transit amplifying progenitors that will lead to differentiated adult tissues is still being determined. Challenges remain in cell expansion, directed differentiation and environmental regulation of pluri- and multi-potent cells that avoid unwanted outcomes in transplantation therapies. Traditional culturing methods are giving way to a revolution in tissue engineering and biofabrication. The key to success is a multidisciplinary partnership of biologists, engineers, material scientists and clinicians. This strategy brings together cutting edge technologies and diverse expertise to bridge nano- to micro- to macroscale communication networks. Here, we discuss prominent technologies being applied to engineer the stem cell and tissue niche in vitro for the construction of 3D tissue architectures with integrated vascular networks.
Professor Miguel Forte will describe research into a new cell therapy at the UK National Stem Cell Network annual science meeting…
Turn back the clock and be healed Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine
They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are induced pluripotent stem cells (or iPS for short). The discovery was that somatic cells from the adult body, whether from a hair, skin biopsy, cord-blood or even adipose tissue, can quite readily be changed back into pluripotent stem cells – ostensibly the state they were in shortly after conception – in the process, erasing the epigenetic modifications that make a brain cell different from, say, a liver cell.
It would be fair to say that these past 12 months have been a watershed year for stem cell science. In years to come we may look back on 2009 and recognise it as the year in which nascent areas of science, medicine and technology came together to slowly nudge stem cell biology into the mainstream. Scientific and academic progress aside, it also may mark the year in which the field first matured to a stage at which commercial viability came to the cusp of realisation.
The promise of stem cell-based therapy is predicated on harnessing the plasticity of stem cell phenotypes to repair or replace damaged tissues. As technologies for detecting, isolating, modifying, and tracking stem cells improve, the very definition of what constitutes a stem cell is now an open question. Addressing this fundamental problem has triggered an explosion [...]
The 4th annual Stem Cells World Congress and exhibition will be held in South San Francisco, the Birthplace of Biotechnology. This year there are two parallel tracks focused specifically on…
Nearly fifty years ago, it was hypothesised that terminally differentiated cells such as fibroblasts could be forced to take on a pluripotent state, similar to the embryonic stem cells (ES cells). The basis of the concept is the observation that all cell types, with minor exceptions, have the same genetic code. The only difference is how the code is read. This ability of differentiated cells to acquire a pluripotent state or, more generally, the process of cell fate conversion is termed cellular reprogramming.
ABB Analytical Measurement Analytik Jena AG Aptalis Pharmaceutical Technologies ASM - Aerosl-Service AG Azbil BioVigilant, Inc. B&W Tek, Inc. bioMérieux BioTrends – Archilex SA BMG LABTECH GmbH Bruker Daltonik GmbH CAMO Software AS Catalent Pharma Solutions Chemspec Europe Ltd CI Precision Dow Chemical Company Ltd EUROGENTEC FOSS NIRSystems, Inc. GE Analytical Instruments Gerresheimer Group HAMAMATSU PHOTONICS EUROPE I Holland Limited IDBS IONIMED Analytik GmbH LI-COR Biosciences Lonza Natoli Engineering Company, Inc. Pall Life Sciences PANalytical B.V. Patheon Inc PhyNexus, Inc. ReAgent Roche Sirius Analytical Instruments Ltd Vala Sciences Veltek Associates Inc.